Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Arterra Bioscience SpA's Revenue for the
six
months ended in Dec. 2025 was €2.10 Mil. Arterra Bioscience SpA's average Accounts Receivable for the
six
months ended in Dec. 2025 was €1.09 Mil.
Hence, Arterra Bioscience SpA's Receivables Turnover for the
six
months ended in Dec. 2025 was 1.91.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Arterra Bioscience SpA Receivables Turnover Related Terms
Arterra Bioscience SpA Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Arterra Bioscience SpA's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:ARBS vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Arterra Bioscience SpA's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arterra Bioscience SpA Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Arterra Bioscience SpA's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arterra Bioscience SpA (MIL:ARBS) has a Receivables Turnover of 1.91 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Arterra Bioscience SpA and its competitors. According to the industry distribution chart, Arterra Bioscience SpA ranks #446 out of 846 companies in the Biotechnology industry, placing it in the top 52.7%.
Is Arterra Bioscience SpA's Receivables Turnover too high?
Arterra Bioscience SpA's current Receivables Turnover is 1.91. The Biotechnology industry median Receivables Turnover is 5.24. Arterra Bioscience SpA's value of 1.91 is 63.5% below this industry median. Based on the distribution chart, Arterra Bioscience SpA ranks #446 out of 846 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Arterra Bioscience SpA has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arterra Bioscience SpA ranks #446 out of 846 companies for Receivables Turnover. This places Arterra Bioscience SpA in the lower half of its industry. The industry median Receivables Turnover is 5.24. Arterra Bioscience SpA's value of 1.91 is 63.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.24, based on 846 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arterra Bioscience SpA's current Receivables Turnover of 1.91 is 63.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Arterra Bioscience SpA and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arterra Bioscience SpA's current Receivables Turnover is 1.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.93, compared to a current price of €3.19 — trading 8.9% above its estimated fair value. The current Receivables Turnover is 1.91 and 63.5% below the Biotechnology industry median of 5.24. Arterra Bioscience SpA's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current Receivables Turnover is 1.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?
Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued.
The current stock price of €3.19 is trading 8.9% above its estimated GF Value™ of €2.93.
GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.
Key valuation signals for MIL:ARBS:
Receivables Turnover: 1.91
GF Value™: €2.93 vs. price of €3.19 (8.9% above fair value)
Industry Position: 63.5% below the Biotechnology median (#446 of 846)
No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
82GF Score
Get the complete analysis for MIL:ARBS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ARBS has been successfully added to your 
